Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 6, June, p. 765–770

doi: 10.17219/acem/94062

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The clinical significance of intrahepatic Th22 cells in liver cirrhosis

Shanyu Qin1,A,D,F, Mei Chen1,B,C, Xiaoyun Guo1,B,F, Wei Luo1,C,D,F, Jiaxu Wang1,B,C,F, Haixing Jiang1,A,E,F

1 Department of Gastroenterology, First Affiliated Hospital of Guangxi Medical University, Nanning, China

Abstract

Background. Th22 cells are a recently identified CD4+ T helper subset and have been implicated in the pathogenesis of certain diseases in humans, but the role of Th22 cells in liver cirrhosis (LC) remains unclear.
Objectives. The aim of the study was to investigate the expression and clinical significance of intrahepatic Th22 cells in LC tissues.
Material and Methods. Samples of liver tissue of 20 LC patients and 12 normal controls (NC) were collected. Interleukin 22 (IL-22), IL-22R1 mRNA and aryl hydrocarbon receptor (AHR) expression were examined using quantitative reverse transcription polymerase chain reaction (RT-PCR). The protein expression of Th22 and CD4+ cells in liver tissue was measured with immunohistochemistry.
Results. The number of intrahepatic Th22 and CD4+ cells increased markedly in LC patients and the number of Th22 cells positively correlated with the number of CD4+ cells (p < 0.05). Moreover, the number of Th22 cells positively correlated with the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as the Child-Pugh score in LC patients (p < 0.05). The expression of IL-22, IL-22R1 and AHR in LC patients was significantly increased compared with the NC group (p < 0.05).
Conclusion. Our findings suggest that the expression of intrahepatic Th22 cells increased in LC patients and was associated with the progression of LC.

Key words

Th22 cells, liver cirrhosis, clinical significance

References (18)

  1. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–1132.
  2. Vierling JM. The immunology of hepatitis B. Clin Liver Dis. 2007;11(4):727–759.
  3. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–863.
  4. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10(8):864–871.
  5. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
  6. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn’s disease and promotes pro-inflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G827–838.
  7. Liu T, Peng L, Yu P, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32(6):1332–1339.
  8. Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–840.
  9. Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol. 2011;55(3):574–581.
  10. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–1669.
  11. Liaw Y-F, Chu C-M. Hepatitis B virus infection. Lancet. 2009;373(9663):582–592.
  12. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol. 2008;2(2):233–242.
  13. Lai R, Xiang X, Mo R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015;63(1):148–155.
  14. Park O, Wang H, Weng H, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology. 2011;54(1):252–261.
  15. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine struc-turally related to IL-10 and inducible by IL-9. J Immunol. 2000;164(44):1814–1819.
  16. Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001;276(4):2725–2732.
  17. Kong X, Feng D, Wang H, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150–1159.
  18. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453(7191):106–109.
© Wroclaw Medical University